Literature DB >> 23073827

Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice.

Amena Archer1, Nicolas Venteclef, Agneta Mode, Matteo Pedrelli, Chiara Gabbi, Karine Clément, Paolo Parini, Jan-Åke Gustafsson, Marion Korach-André.   

Abstract

The liver plays a pivotal role in the physiological adaptation to fasting and a better understanding of the metabolic adaptive responses may give hints on new therapeutic strategies to control the metabolic diseases. The liver X receptors (LXRs) are well-established regulators of lipid and glucose metabolism. More recently fibroblast growth factor 21 (FGF21) has emerged as an important regulator of energy homeostasis. We hypothesized that the LXR transcription factors could influence Fgf21 expression, which is induced in response to fasting. Wild-type, LXRα(-/-), and LXRβ(-/-) mice were treated for 3 d with vehicle or the LXR agonist GW3965 and fasted for 12 h prior to the killing of the animals. Interestingly, serum FGF21 levels were induced after fasting, but this increase was blunted when the mice were treated with GW3965 independently of genotypes. Compared with wild-type mice, GW3965-treated LXRα(-/-) and LXRβ(-/-) mice showed improved insulin sensitivity and enhanced ketogenic response at fasting. Of note is that during fasting, GW3965 treatment tended to reduce liver triglycerides as opposed to the effect of the agonist in the fed state. The LXR-dependent repression of Fgf21 seems to be mainly mediated by the recruitment of LXRβ onto the Fgf21 promoter upon GW3965 treatment. This repression by LXRβ occurs through the recruitment and stabilization of the repressor complex composed of retinoid-related orphan receptor-α/Rev-Erbα/histone deacetylase 3 onto the Fgf21 promoter. Our data clearly demonstrate that there is a cross talk between the LXR and FGF21 signaling pathways in the adaptive response to fasting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073827      PMCID: PMC5416953          DOI: 10.1210/me.2012-1151

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  53 in total

Review 1.  Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.

Authors:  L Laffel
Journal:  Diabetes Metab Res Rev       Date:  1999 Nov-Dec       Impact factor: 4.876

Review 2.  Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis.

Authors:  S J Pilkis; D K Granner
Journal:  Annu Rev Physiol       Date:  1992       Impact factor: 19.318

3.  GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus.

Authors:  Tomas Jakobsson; Nicolas Venteclef; Gudrun Toresson; Anastasios E Damdimopoulos; Anna Ehrlund; Xiaohua Lou; Sabyasachi Sanyal; Knut R Steffensen; Jan-Ake Gustafsson; Eckardt Treuter
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

4.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Authors:  Alexei Kharitonenkov; Victor J Wroblewski; Anja Koester; Yun-Fei Chen; Cathleen K Clutinger; Xenia T Tigno; Barbara C Hansen; Armen B Shanafelt; Garret J Etgen
Journal:  Endocrinology       Date:  2006-10-26       Impact factor: 4.736

Review 5.  Liver X receptors in cardiovascular and metabolic disease.

Authors:  R Geyeregger; M Zeyda; T M Stulnig
Journal:  Cell Mol Life Sci       Date:  2006-03       Impact factor: 9.261

6.  Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity.

Authors:  Fredirick L Mashili; Reginald L Austin; Atul S Deshmukh; Tomas Fritz; Kenneth Caidahl; Katrin Bergdahl; Juleen R Zierath; Alexander V Chibalin; David E Moller; Alexei Kharitonenkov; Anna Krook
Journal:  Diabetes Metab Res Rev       Date:  2011-03       Impact factor: 4.876

7.  Lxralpha deficiency hampers the hepatic adaptive response to fasting in mice.

Authors:  Maaike H Oosterveer; Theo H van Dijk; Aldo Grefhorst; Vincent W Bloks; Rick Havinga; Folkert Kuipers; Dirk-Jan Reijngoud
Journal:  J Biol Chem       Date:  2008-07-08       Impact factor: 5.157

8.  Identification of oxysterol 7alpha-hydroxylase (Cyp7b1) as a novel retinoid-related orphan receptor alpha (RORalpha) (NR1F1) target gene and a functional cross-talk between RORalpha and liver X receptor (NR1H3).

Authors:  Taira Wada; Hong Soon Kang; Martin Angers; Haibiao Gong; Shikha Bhatia; Shaheen Khadem; Songrong Ren; Ewa Ellis; Stephen C Strom; Anton M Jetten; Wen Xie
Journal:  Mol Pharmacol       Date:  2007-11-30       Impact factor: 4.436

9.  Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.

Authors:  Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu
Journal:  Diabetes       Date:  2008-02-05       Impact factor: 9.461

10.  A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.

Authors:  Florian Blaschke; Yasunori Takata; Evren Caglayan; Alan Collins; Peter Tontonoz; Willa A Hsueh; Rajendra K Tangirala
Journal:  Circ Res       Date:  2006-11-16       Impact factor: 17.367

View more
  13 in total

1.  Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells.

Authors:  Tao Hu; Weiliang Huang; Zhihui Li; Maureen A Kane; Lei Zhang; Shiew-Mei Huang; Hongbing Wang
Journal:  Toxicol Appl Pharmacol       Date:  2020-07-04       Impact factor: 4.219

2.  The mysterious relationship between reproduction and longevity.

Authors:  Hugo Aguilaniu
Journal:  Worm       Date:  2015-03-06

Review 3.  Nuclear receptors and nonalcoholic fatty liver disease.

Authors:  Matthew C Cave; Heather B Clair; Josiah E Hardesty; K Cameron Falkner; Wenke Feng; Barbara J Clark; Jennifer Sidey; Hongxue Shi; Bashar A Aqel; Craig J McClain; Russell A Prough
Journal:  Biochim Biophys Acta       Date:  2016-03-04

4.  Glucocorticoid receptor-PPARα axis in fetal mouse liver prepares neonates for milk lipid catabolism.

Authors:  Gianpaolo Rando; Chek Kun Tan; Nourhène Khaled; Alexandra Montagner; Nicolas Leuenberger; Justine Bertrand-Michel; Eeswari Paramalingam; Hervé Guillou; Walter Wahli
Journal:  Elife       Date:  2016-07-01       Impact factor: 8.140

5.  FGF21 mediates the lipid metabolism response to amino acid starvation.

Authors:  Ana Luísa De Sousa-Coelho; Joana Relat; Elayne Hondares; Albert Pérez-Martí; Francesc Ribas; Francesc Villarroya; Pedro F Marrero; Diego Haro
Journal:  J Lipid Res       Date:  2013-05-09       Impact factor: 5.922

6.  Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice.

Authors:  Nicola Morrice; George D Mcilroy; Seshu R Tammireddy; Jennifer Reekie; Kirsty D Shearer; Mary K Doherty; Mirela Delibegović; Phillip D Whitfield; Nimesh Mody
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

Review 7.  Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD.

Authors:  Takeshi Inagaki
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-23       Impact factor: 5.555

8.  Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3.

Authors:  Yan Leng; Junyu Wang; Zhifei Wang; Hsiao-Mei Liao; Monica Wei; Peter Leeds; De-Maw Chuang
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 5.176

Review 9.  FGF21 as Modulator of Metabolism in Health and Disease.

Authors:  Caterina Tezze; Vanina Romanello; Marco Sandri
Journal:  Front Physiol       Date:  2019-04-17       Impact factor: 4.566

10.  Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.

Authors:  Mingming Gao; Le Bu; Yongjie Ma; Dexi Liu
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.